News

The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.
The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.